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Abstract Two L1,3galactosyltransferases are detected in hu-
man colon cells : one corresponds to L3GalT1, the other
(L3GalTx) is found to be different from any cloned L3GalT
since in vitro it utilizes GlcNAc very efficiently under specific
reaction conditions. Expression of L3GalT1 transcript is high in
normal colon mucosa and control neuroectodermal cells, which
do not express sialyl-Lewis a antigen, and low in colon
adenocarcinoma cells, as assessed by competitive RT-PCR.
L3GalTx activity is high in adenocarcinoma cells expressing
sialyl-Lewis a and undetectable in all other cells, suggesting
differential involvement and opposite regulation of such enzymes
during carcinogenesis.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
There is increasing evidence that glycosyltransferases are
coded by families of multiple related genes whose expression
is carefully regulated in di¡erent tissues and in di¡erent phys-
iological or pathological states [1^4]. The GalL1-3GlcNAc
disaccharide is the core sequence (type 1 structure) of onco-
developmental antigens such as sialyl-Lea or Leb [5,6], but is
also reported in the saccharide chain of normal tissue glyco-
proteins [7,8], and as a target of auto antibodies in neuro-
pathies [9,10]. The enzymes involved in its biosynthesis are
still not well de¢ned and their regulation is totally unknown.
Four members of the L1,3GalT family have been recently
cloned [11]. L3GalT1, L3GalT2, and L3GalT3 are considered
to be able to synthesize the type 1 structure, while it is though
that L3GalT4 is able to synthesize the GalL1-3GalNAc se-
quence. L3GalT1 and L3GalT2 use GlcNAc as acceptor in
vitro very poorly, and L3GalT3 does not use it at all. Con-
versely, a L1,3GalT activity expressed in human colon adeno-
carcinoma cells was found to e⁄ciently use GlcNAc as accept-
or, but only at very high concentrations, and to require rather
high concentrations of donor UDP-Gal too [12].
In this work, we investigated whether any cloned L3GalT
corresponds to the enzyme we detected in human colon ad-
enocarcinoma cells, and whether the expression is related to
that of type 1 chain Lewis antigens. To this end, we deter-
mined the expression levels of cloned L3GalTs by Northern
blot and RT-PCR in human colon adenocarcinoma cell line
COLO-205, that expresses Lewis type 1 antigens and
L1,3GalT activity [12]. On the basis of the results, we used
competitive RT-PCR to quantitate the RNA transcripts of
L3GalT1 and two glycosyltransferases involved in the synthe-
sis of type 1 chain Lewis antigens (Fuc-TIII and FUT2), in
COLO-205 and other human cells derived from colon adeno-
carcinomas and normal mucosa. We also screened a COLO-
205 cDNA library by colony hybridization using a L3GalT1
fragment as a probe, and studied the GalT activity directed by
an isolated cDNA clone, upon expression in CHO cells, by
immunostaining and in vitro enzyme assay.
2. Materials and methods
2.1. Materials
GlcNAc, GlcNAcL1-O-benzyl (benzyl-GlcNAc), GlcNAcL1-O-
phenyl (phenyl-GlcNAc), GlcNAcL1-3GalL1-O-methyl, GlcNAcL1-
6ManK1-O-methyl, GlcNAcL1-6GlcNAc, UDP-Gal, K-lactalbumin,
egg ovalbumin, bovine asialomucin, asialofetuin, and FITC conjugate
goat anti-mouse IgG were from Sigma. UDP-[6-3H]Gal was from
Amersham. Anti-sialyl-Lea (0.9 mg/ml) monoclonal antibody was pre-
pared by protein A-Sepharose a⁄nity chromatography of the culture
media of hybridoma 1116-NS-19-9 (ATCC HB-8059).
2.2. Cell lines
Human colon adenocarcinoma COLO-205, HCT-15 and HT-29
cells were cultured as previously reported [12]. Human colon normal
mucosa cells FHC (ATCC CRL-1831) were cultured in Dulbecco’s
modi¢ed Eagle’s medium/Ham F:12 (1:1) mixture containing 10%
fetal bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin,
2 mM L-Glu, and supplemented with 10 ng/ml cholera toxin, 5 Wg/
ml insulin, 5 Wg/ml transferrin, and 100 ng/ml hydrocortisone. Human
neuroblastoma IMR-32 (ATCC CCL-127) and melanoma WM266-4
(ATCC CRL-1676) cells were cultured in Eagle’s minimum essential
medium containing 10% fetal bovine serum, 100 U/ml penicillin, 100
mg/ml streptomycin, 2 mM L-Glu, and supplemented with 0.1 mM
non-essential amino acids, 1.0 mM sodium pyruvate, and Earle’s bal-
anced salt solution. CHO cells expressing Polyoma virus T antigen
and human Fuc-TIII (CHO-T-FT), a gift of J.B. Lowe (University of
Michigan), were cultured in minimum essential medium (K-modi¢ca-
tion) containing 10% fetal bovine serum, 100 U/ml penicillin, 100 mg/
ml streptomycin, 2 mM L-Glu, and supplemented with 0.5 mg/ml
(active) G418 and 750 U/ml Hygromycin B. They were transiently
transfected with plasmid DNA using the procedure reported [13].
2.3. Isolation of a cDNA clone
Total and poly(A) RNAs were prepared as reported [12]. For
COLO-205 cDNA library construction, poly(A) RNA was reverse
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transcribed in separate reactions as follows. Reaction 1 contained, in
40 Wl volume, 10 mM Tris-HCl pH 8.3, 50 mM KCl, 5 mM MgCl2,
1000 U/ml human placental ribonuclease inhibitor, 1 mM of each
deoxynucleotide triphosphate, 2.5 WM random hexanucleotide pri-
mers, 2500 U/ml Moloney Murine Leukemia virus (MuLV) reverse
transcriptase (Perkin Elmer), and 50 mg/ml freshly denatured (5 min
at 65‡C, 2 min on ice) poly(A) RNA.
Reaction 2 contained, in 40 Wl volume, 50 mM Tris-HCl pH 8.3, 75
mM KCl, 3 mM MgCl2, 1000 U/ml human placental ribonuclease
inhibitor, 1 mM of each deoxynucleotide triphosphate, 3.5 WM ran-
dom hexanucleotide primers, 2500 U/ml MuLV reverse transcriptase
(Amersham), and 50 mg/ml freshly denatured poly(A) RNA.
Reaction 3 contained, in 40 Wl volume, 50 mM Tris-HCl pH 8.3, 50
mM KCl, 5 mM MgCl2, 1000 U/ml human placental ribonuclease
inhibitor, 1 mM of each deoxynucleotide triphosphate, 3.5 WM ran-
dom hexanucleotide primers, 1000 U/ml Avian Myeloblastosis virus
reverse transcriptase (Amersham), and 50 mg/ml freshly denatured
poly(A) RNA. Reactions were kept 10 min at room temperature,
40 min at 37‡C and 45 min at 42‡C. Second strand cDNA was syn-
thesized from the obtained ¢rst strand cDNA (0.1 ml equal mixture of
each reaction) by a commercial kit (cDNA plus, Amersham) following
the manufacturer’s recommendations. Blunt ended cDNA was ligated
to a BstXI adapter (upper strand: 5P-GCTTCTCGAGCTTTAGAG-
CACA; lower strand: 5P-CTCTAAAGCTCGAGAAGC), size frac-
tionated by a double passage on a Sephacryl 500 column (Gibco),
cloned in the BstXI sites of pCDM8 vector, and the ligated material
electroporated into E. coli strain MC1061/P3. Calculated library size
was greater than 107 recombinants per 1 Wg starting RNA, and back-
ground lower than 1%. The average insert size, determined by XhoI
digestion of plasmid DNA extracted from library pools of 500, 2000,
and 5000 recombinants, was 1.5 Kbp. Primary recombinants obtained
upon electroporation were plated on agar plates (about 10 000 colo-
nies per 150 mm plates) and screened by conventional colony hybrid-
ization using a [32P]-labeled L3GalT1 probe. Probe was the 743 bp
PCR product reported in Table 1. Blots were washed in 2USSC (0.30
M NaCl and 0.03 M sodium citrate) containing 0.5% SDS for 15 min
at room temperature (twice), and then for 30 min at 55‡C. A 1.9 Kbp
insert isolated from a single positive colony (COLO-205 L3GalT1)
was sequenced by the dideoxy chain termination method using an
automated procedure.
2.4. RT-PCR and competitive RT-PCR
First strand cDNA was prepared from poly(A) RNA as for
cDNA library construction (reaction 2), and an amount correspond-
ing to 0.25 Wg of reverse transcribed RNA (5 Wl of cDNA synthesis
reaction) submitted to PCR ampli¢cation. Standard ampli¢cation re-
action contained, in a total volume of 50 Wl, 0.1 mM of each deoxy-
nucleotide triphosphate, 10 mM Tris/HCl, pH 8.8, 50 mM KCl, 1 mM
MgCl2, 1% Triton X-100, 250 ng of each primer (see Table 1), and 2.5
U of Taq polymerase (Eurobio). Reactions were incubated as follows:
a single treatment at 94‡C for 2.0 min, followed by a cycle consisting
of 1.5 min at 94‡C (melting) and 3.5 min at 72‡C (annealing plus
extension), that was repeated 25 or 35 times. A ¢nal extension step
was performed at 72‡C for 8 min. Oligonucleotide primer pairs were
designed on the basis of published sequences as reported in Table 1.
For competitive RT-PCR [14], ¢rst strand cDNA was prepared under
the same conditions as reported above (reaction 2), but using 0.4 WM
oligo(dT)16 as primer and freshly denatured total RNA (250 Wg/ml) as
template. In preliminary experiments, 1 Wl aliquots of the cDNA syn-
thesis reactions were mixed with di¡erent amounts of linear compet-
itors (from 1 fg to 100 pg) and submitted to standard PCR ampli¢-
cation for 25^35 cycles. On the basis of the obtained results, di¡erent
amounts of cDNA (0.5^2.0 Wl of ¢rst strand synthesis reactions) were
then mixed with 45 pg of L-actin linear competitor cDNA and sub-
mitted to PCR ampli¢cations for 25 cycles, until the amount of cDNA
that provides comparable results was selected (Fig. 2, upper part). In
the ¢nal experiments, normalized cDNA aliquots were mixed with
single amounts of each competitor (25 fg for L3GalT1, 100 fg for
Fuc-TIII, and 50 fg for FUT2), and submitted to PCR ampli¢cation
(35 cycles for L3GalT1, 30 cycles for Fuc-TIII and FUT2). In all
cases, parallel PCR ampli¢cations were performed on known amounts
of standard linear cDNAs pre-mixed with the competitors. Aliquots
(10 Wl) of PCR reactions were analyzed by 1% agarose gel electro-
phoresis and visualized by staining with ethidium bromide under UV
light. Competitor cDNAs were prepared by removing short restriction
fragments from the regions of ampli¢cation as follows: a 280 bp
fragment was removed from L-actin by RcaI digestion, a 279 bp frag-
ment from L3GalT1 by EcoRV/XmnI digestion, a 136 bp fragment
from Fuc-TIII by KpnI digestion, and a 196 bp fragment from FUT2
by BamHI/PstI digestion (Table 1). Truncated cDNAs were self-li-
gated, cloned, linearized, quantitated, and diluted.
Northern blotting was performed on denatured poly(A) RNA
(3 Wg) as reported [12].
2.5. Enzyme assays
Cells were harvested, washed, and resuspended as described [12].
L3GalT1 was determined in a reaction mixture containing, in a ¢nal
volume of 20 Wl, 0.1 M HEPES bu¡er, pH 7.4, 10 mM MnCl2, 0.5
mg/ml Triton X-100, 1 mg/ml K-lactalbumin, 60 WM donor UDP-
[3H]Gal, speci¢c radioactivity 20 mCi/mmol, 40 mM acceptor
GlcNAc, and 0.2^2.0 mg/ml cell protein. Incubation was done at
37‡C for 90 min. L3GalTx was determined in a reaction mixture as
L3GalT1 but containing 1.0 mM donor UDP-[3H]Gal, speci¢c radio-
activity 5 mCi/mmol, 0.8 M acceptor GlcNAc, and 0.1^2.0 mg/ml cell
protein. Incubation was done at 37‡C for 60 min. Reaction products
were assayed by Dowex chromatography (saccharide acceptors) or
phosphotungstic acid precipitation (glycoprotein acceptor), and radio-
activity incorporation was determined by liquid scintillation counting
as reported [12].
2.6. Immuno£uorescence and panning
Cells were detached, recovered, washed, and stained in suspension
as reported [12], using 1:500 dilution of monoclonal antibodies anti-
sialyl-Lea or anti-Lea. Alternatively, cells grown on tissue culture
slides were washed with PBS, ¢xed with 3.7% formaldehyde in PBS,
washed three times with PBS, and stained as above for cell suspen-
sions. Fluorescence was determined by £ow cytometry and micro-
scopy.
For panning, CHO-T-FT cells transfected with L3GalT1 cDNA
were detached from plates (100 mm), washed, suspended in staining
medium (4 ml/transfected plate), and placed on panning dishes (4 ml/
dish), prepared by covering Petri dishes with anti-sialyl-Lea antibody,
as reported [13]. Panning was performed at 4‡C for 1 h. Non-adherent
cells were removed by washing three times with PBS, while adherent
cells were detached, washed, and processed.
3. Results
3.1. Detection of L1,3GalT transcripts in human colon
adenocarcinoma cells COLO-205
To determine whether the L1,3GalT activity detected in
COLO-205 cells is due to one of the cloned L3GalT genes,
COLO-205 cDNA was ampli¢ed by PCR using oligonucleo-
tide primers deduced from the reported sequences (Table 1).
Ampli¢cation was detected with L3GalT1 primers, while only
Fig. 1. Northern blot analysis of COLO-205 and control WM266-4
cells. Poly(A) RNA was separated by formaldehyde gel electropho-
resis, and blotted onto a nitrocellulose membrane that was probed
with [32P]-labeled L3GalT1 probe. The same membrane was sequen-
tially stripped and reprobed using [32P]-labeled Fuc-TIII and L-actin
probes, respectively.
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a faint spot was obtained with L3GalT2 primers, and no sig-
nal with L3GalT3 primers (not shown). COLO-205 poly(A)
RNA was analyzed by Northern blot using a L3GalT1 probe,
but no spot was detected in this case, suggesting low expres-
sion of L3GalT1 (Fig. 1). A random hexamer primed cDNA
library prepared from COLO-205 cells was screened at low
stringency by colony hybridization using the same L3GalT1
probe. A positive colony was isolated and the obtained 1.9
Kbp cDNA insert subcloned in pcDNAI vector. Direct DNA
sequencing (GenBank accession AF117222) indicated the
presence of an open reading frame of 978 bp whose trans-
lation predicted an amino acid sequence identical to
L3GalT1 (GenBank accession E07739), con¢rming the expres-
sion of the enzyme in COLO-205.
3.2. L1,3GalT activities expressed in colon cells
Cloned L3GalT1 was expressed in CHO-T-FT cells, a line
able to replicate plasmids with the Polyoma origin of replica-
tion and synthesize K1,4fucosyl linkage through expression of
Polyoma virus large T antigen and human Fuc-TIII, respec-
tively. Transiently transfected cells react with anti-sialyl-Lea
and Lea antibodies as assessed by immuno£uorescence, while
mock transfected cells do not. L3GalT1 transfected cells ex-
pressing sialyl-Lea antigen were isolated by panning, and used
as enzyme source for determining L1,3GalT activity towards
GlcNAc as acceptor. At concentrations of 40 mM GlcNAc
and 60 WM UDP-Gal, a weak K-lactalbumin insensitive activ-
ity is detected in such cells, but not in mock transfected CHO-
T-FT cells, as expected for L3GalT1. The activity is not stimu-
lated but rather inhibited by higher GlcNAc concentrations,
while that expressed in COLO-205 cells (L3GalTx) is strongly
stimulated. WM266-4 cells, a melanoma cell line known to
express high levels of L3GalT1, show similar behaviour to
the L3GalT1 transfected CHO-T-FT cells (Table 2). Interest-
ingly, a similar K-lactalbumin insensitive galactosyltransferase
activity, not stimulated by high GlcNAc concentration, is
present in FHC cells, a line derived from normal human colon
mucosa. This suggests the presence of L3GalT1 in this cells
too. However, conclusive evidence for the actual L1,3 nature
of the activity is lacking since the low amount of product
formed did not allow for its chemical characterization.
L1,3GalT activity was thus determined in the same cells using
high GlcNAc and UDP-Gal concentrations, as previously es-
tablished in COLO-205 cells. The results indicate that under
such conditions genuine L3GalTx activity is detected in
COLO-205 and HT-29 cells only, but not in FHC or HCT-
15 cells, nor in WM266-4 or IMR-32 cells (Table 2). L3GalTx
is found to e⁄ciently use some oligosaccharide acceptors,
mostly GlcNAcL1-3GalL1-O-methyl, but not others such as
benzyl-GlcNAc, or any tested glycoprotein (Table 3). These
data indicate that L3GalTx is present in some colon adeno-
carcinoma cell lines but is not detectable in cells from normal
colon mucosa or neuroectodermal origin, and is functionally
di¡erent from L3GalT1 and L3GalT2.
3.3. Quantitation of L3GalT1 transcript in di¡erent cells by
competitive RT-PCR
To determine the expression level of L3GalT1 in the di¡er-
ent cells studied, total RNA was reversed transcribed using an
oligo(dT) primer, and the amount of obtained cDNA normal-
Table 1
Oligonucleotide primers used for RT-PCR analyses
RNA Primers Size (bp) of ampli¢ed DNA GenBank accession
Target Competitor
L-actin U 5P-CTGAACCCCAAGGCCAACCGCGAG 754 474 AB004047
L 5P-CCTGCTTGCTGATCCACATCTGCTGGAAG
L3GalT1 U 5P-GCTGGGCCAGCGCTCTCTGGTAC 743 464 E07739
L 5P-GTGAAGCAGCCTTGTGTGGAGTGAG
L3GalT2 U 5P-GCCAAAAGGTCTCTGTTCCGCACTC 817 Y15014
L 5P-GATTGGGTGCATATCCTCGCATTAGG
L3GalT3 U 5P-ATGGCCTCGGCTCTCTGGACTGTCC 768 Y15062
L 5P-CATTTCATAGATCCTTGGCACCAAATCTCTGGAC
Fuc-TIII U 5P-GATCTGGTTCAACTTGGAGCCACCCCCT 750 614 X53578
L 5P-CAGCAGGTGAGGCCCCAGGCAG
FUT2 U 5P-GCGGCTAGCGAAGATTCAAGCCATG 718 522 U17894
L 5P-GCCCTCAATGCCATCGCCAGCAAACAC
U, upper strand primer; L, lower strand primer.
Table 2
Galactosyltransferase speci¢c activity measured in transfected and control cells under di¡erent reaction conditions
Cells Donor UDP-Gal 60 WM 1.0 mM
acceptor GlcNAc 40 mM 600 mM 800 mM
K-lactalbumin 3 + + +
L3GalT1 transfected sialyl-Lea positive CHO-T-FT 17.7 8.7 5.7 6 0.5
mock transfected sialyl-Lea negative CHO-T-FT 11.5 6 0.5 6 0.5 6 0.5
COLO-205 48.8 10.9 145 360
HT-29 n.d. n.d. n.d. 25
FHC 5.0 2.5 2.1 6 0.5
IMR-32 n.d. n.d. n.d. 6 0.5
WM266-4 4.8 4.1 3.2 6 0.5
Values are expressed as nanomoles/mg protein/h transferred Gal.
N.d., not determined.
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ized with respect to L-actin as described in Section 2 (Fig. 2
upper part). Normalized cDNA aliquots were then mixed with
linear competitor cDNAs corresponding to truncated forms of
L3GalT1, Fuc-TIII, and FUT2, respectively, submitted to
PCR ampli¢cation, and the obtained products analyzed by
gel electrophoresis (Fig. 2).
L3GalT1 transcript is expressed at low or very low levels in
the examined human colon adenocarcinoma cell lines, while it
is expressed at a much higher level in FHC cells, the line
derived from normal human colon mucosa. The expression
level in FHC is comparable to that measured in a neuroblas-
toma cell line. In parallel experiments performed using the
corresponding primers and competitors, Fuc-TIII transcript
was absent in neuroblastoma cells, but was expressed in
HCT-15 and HT-29 adenocarcinoma cells, as well as in
FHC cells, and the expression was very high in COLO-205.
FUT2 was found to be expressed mostly in HCT-15 and
COLO-205, and was also detectable in HT-29, FHC, and
even neuroblastoma cells. The quantitative results are sum-
marized in Table 4.
3.4. Expression of sialyl-Lea and Lea antigens on the cell
surface
To determine the involvement of the di¡erent L1,3GalTs in
the biosynthesis of Lewis type 1 antigens, their expression was
determined by immuno£uorescence using mouse anti-sialyl-
Lea and anti-Lea monoclonal antibodies, and secondary
FITC conjugate anti-mouse antibody (Fig. 3). Fluorescence
with both anti-sialyl-Lea and anti-Lea antibodies is very bright
in COLO-205 cells, and moderately bright in HT-29 cells,
while is totally negative in FHC, HCT-15, IMR-32, and
WM266-4 cells. When these results are compared to L3GalT
activity and expression, it appears that the presence of sialyl-
Lea and Lea antigens on the cell surface is not related to
L3GalT1 expression, but rather depends on L3GalTx activity.
Table 3
Acceptor speci¢city of L3GalTx
Acceptor mM COLO-205 (0.1 mg/ml cell protein) HCT-15 (1.0 mg/ml cell protein)
GlcNAc 800 42.9 6 0.5
Benzyl-GlcNAc 40 7.7 0.8
10 0.9 3.5
Phenyl-GlcNAc 40 22.3 6 0.5
10 12.7 2.0
GlcNAcL1-3GalL1-O-methyl 10 68.7 10.3
2.5 31.3 4.3
GlcNAcL1-6ManK1-O-methyl 40 20.6 6 0.5
10 10.9 1.1
GlcNAcL1-6GlcNAc 10 11.1 1.4
mg/ml
Ovalbumin 10 0.9 3.2
Asialomucin 10 1.5 4.6
Asialofetuin 10 6 0.5 6 0.5
Values are expressed as nanomoles/ml/h transferred Gal. Enzyme activity is considered to be L3GalTx related only when levels in COLO-205
cells are higher than levels obtained using excess of HCT-15 protein.
Table 4
Quanti¢cation of glycosyltransferase transcripts in di¡erent cells by
competitive RT-PCR
Transcript Cells
IMR-32 FHC HT-29 HCT-15 COLO-205
L-actin 1000 1000 1000 1000 1000
L3GalT1 1.59 1.42 0.17 0.16 0.41
Fuc-TIII 6 0.05 0.28 0.21 0.72 11.7
FUT2 0.10 0.19 0.19 0.74 0.52
Quanti¢cation was performed by densitometric scanning of the neg-
ative ¢lms of gels in Fig. 2. The amounts of ampli¢ed target
cDNAs were calculated from their respective standard curves and
normalized by those for L-actin.
Fig. 2. Competitive RT-PCR analysis of glycosyltransferase tran-
scripts in di¡erent cells. Single-stranded cDNA reverse transcribed
from total RNA of di¡erent cells, or standard linear cDNAs, were
mixed with competitor (truncated) cDNAs and subjected to 25
cycles (L-actin), 35 cycles (L3GalT1), or 30 cycles (Fuc-TIII and
FUT2) of PCR. Primers and PCR product length are indicated in
Table 1. One ¢fth aliquot of each ampli¢cation reaction was electro-
phoresed in 1% agarose gel and visualized by staining with ethidium
bromide.
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4. Discussion
We found that at least two di¡erent L1,3GalTs are ex-
pressed in human colon mucosa. One is L3GalT1, that is
more highly expressed in normal mucosa than in adenocarci-
noma cell lines, and the other, that we recently reported [12]
as a counterpart of a puri¢ed pig trachea L1,3GalT [15], is
expressed in some colon adenocarcinoma cells but not in nor-
mal mucosa. Such L1,3GalT activity e⁄ciently utilizes
GlcNAc as acceptor but only at very high concentrations,
and also requires rather high concentrations of UDP-Gal as
donor, while L3GalT1 does not e⁄ciently use GlcNAc as
acceptor and requires low UDP-Gal concentrations, as previ-
ously reported [11,12]. Moreover, the acceptor speci¢city of
this L1,3GalT is di¡erent from that reported for L3GalT1 and
L3GalT2 [11]. It thus appears to be a distinct enzyme
(L3GalTx) and we propose it as a ¢fth member of the
L3GalT gene family. Its speci¢c activity correlates with the
amount of Lea and sialyl-Lea antigens on the cell surface,
while the expression of L3GalT1 transcript does not.
In a previous report, no cloned L3GalT was detected in
human colon adenocarcinoma cells by Northern blot [11].
We found that in COLO-205 cells L3GalT1 is well detected
by RT-PCR, but not by Northern blot, and that a very faint
spot is also formed using L3GalT2 primers, while L3GalT3 is
not detected at all. We also isolated a cDNA clone from a
COLO-205 cDNA library that was found to be virtually iden-
tical to the reported L3GalT1 sequence. Taken together these
data indicate that L3GalT1 expression is not restricted to cells
of neuroectodermal origin but includes cells of epithelial ori-
gin. In particular, while L3GalT1 expression is low in colon
adenocarcinoma cells, it is much higher in FHC cells, which
are derived from human fetal normal mucosa and considered
to be most probably epithelial in nature. Interestingly, FHC
cells do not express Lea or sialyl-Lea antigens, even if they
express a low but detectable amount of Fuc-TIII in addition
to L3GalT1, and do not express detectable levels of L3GalTx.
Analogously, IMR-32 and WM266-4 cells, that express high
levels of L3GalT1 transcript but no detectable L3GalTx activ-
ity, lack sialyl-Lea and Lea expression. However these cells do
not express detectable Fuc-TIII. Moreover, the human colon
adenocarcinoma cell line HCT-15, that expresses L3GalT1
and even more Fuc-TIII, but no detectable L3GalTx, does
not present any detectable sialyl-Lea or Lea antigens on the
surface. Taken together these results indicate that L3GalTx is
involved in the biosynthesis of type 1 chain Lewis antigens in
vivo, while L3GalT1 is not. On the other hand, expression of
cloned L3GalT1 in CHO-T-FT cells led to synthesis of sialyl-
Lea and Lea. Since CHO cells express large amounts of N-
glycans containing lactosamine repeats [16], while sialyl-Lea
and Lea are mostly carried by mucins in human colon adeno-
carcinomas [17^19], we believe that the di¡erential expression
of L3GalT1 and L3GalTx a¡ects distinct glycosylation path-
ways involving discrete acceptor molecules. In this context, it
is worth noting that the normal counterparts of CEA, NFA-2
and NCA-2, contain more GalL1-3GlcNAc residues than
CEA on their sugar chains, and that such residues mostly
form the GalL1-3GlcNAcL1-3GalL1-4GlcNAcL1-R outer
chain sequence [20^22]. This di¡erence was found to be asso-
ciated with a lower expression of a L1,3GalT activity in nor-
mal colon mucosa than in adenocarcinomas, as measured with
GlcNAcL1-3GalL1-4Glc as acceptor [23]. In conclusion, we
suggest that L3GalT1 is down-regulated in colon adenocarci-
nomas and is a candidate enzyme involved in L1,3galactosyl-
ation of complex type N-glycans such as those present on
NFA-2, NCA-2, and CEA, while L3GalTx presumably acts
on mucin substrates and is up-regulated in colon adenocarci-
nomas expressing type 1 chain tumor markers. Up-regulation
of other glycosyltransferases in human colon cancer has been
recently reported using the competitive RT-PCR method [24].
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